{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:46:15Z","timestamp":1784155575265,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"crossref","award":["Vici Grant 09150181910040"],"award-info":[{"award-number":["Vici Grant 09150181910040"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Migraine is a debilitating disorder, and while the introduction of monoclonal antibodies (mAbs) has led to efficacious and tolerable responses, a substantial number of patients are so-called \u201cnon-responders\u201d. We introduce reasons for this insufficient response, including insufficient blockade of Calcitonin Gene-Related Peptide (CGRP) or its receptor. We present a clinical case, i.e. a female migraine patient who mistakenly administered supratherapeutic (three-fold higher) doses of erenumab leading to more efficacious clinical responses without any side-effects. This example illustrates that the initial dosages might have been too low, resulting in a remaining undesired increased effect of CGRP. While a capsaicin forearm model has repeatedly been used to evaluate the pharmacokinetic-pharmacodynamic relationship of mAbs, we provide directions to revisit or reconsider dose-finding and dose-ranging of these drugs. These directions include (i) refinement and application of a capsaicin forehead model (instead of a forearm model) to study trigeminovascular activity and improve dosing, and (ii) reconsideration of trial populations. Indeed, the dose-finding studies were mainly performed in relatively young and normal-weight males, while most phase III\/IV trials are marked by a high female-to-male ratio, mainly consisting of overweight to obese females. Considering these aspects in future trials could optimize healthcare for a larger proportion of migraine patients.<\/jats:p>","DOI":"10.1186\/s10194-023-01602-4","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T07:02:03Z","timestamp":1686294123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Revisiting dose-finding of monoclonal antibodies in migraine"],"prefix":"10.1186","volume":"24","author":[{"given":"Linda","family":"Al-Hassany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Karsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"issue":"19","key":"1602_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migrainea. N Engl J Med 383(19):1866\u201376","journal-title":"N Engl J Med"},{"issue":"4\u20135","key":"1602_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42(4\u20135):291\u2013301","journal-title":"Cephalalgia"},{"issue":"1","key":"1602_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-022-01408-w","volume":"23","author":"R Ornello","year":"2022","unstructured":"Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B et al (2022) Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain 23(1):38","journal-title":"J Headache Pain"},{"issue":"5","key":"1602_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13(5):361\u2013378","journal-title":"J Headache Pain"},{"issue":"5","key":"1602_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2125.2007.02939.x","volume":"64","author":"BJ Van der Schueren","year":"2007","unstructured":"Van der Schueren BJ, De Hoon JN (2007) Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. Br J Clin Pharmacol 64(5):580\u2013590","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1602_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/cpt.799","volume":"103","author":"J de Hoon","year":"2018","unstructured":"de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS et al (2018) Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther 103(5):815\u2013825","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1602_CR7","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s11095-017-2183-6","volume":"34","author":"T Vu","year":"2017","unstructured":"Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L et al (2017) Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm Res 34(9):1784\u20131795","journal-title":"Pharm Res"},{"key":"1602_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fphar.2017.00740","volume":"8","author":"D Monteith","year":"2017","unstructured":"Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC et al (2017) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (Galcanezumab) in healthy volunteers. Front Pharmacol 8:740","journal-title":"Front Pharmacol"},{"issue":"5","key":"1602_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/cpdd.929","volume":"10","author":"J Fiedler-Kelly","year":"2021","unstructured":"Fiedler-Kelly J, Raddad E, Hoon J, Ludwig EA, Passarell J, Kielbasa W et al (2021) Relationship of the calcitonin gene-related peptide monoclonal antibody Galcanezumab pharmacokinetics and capsaicin-induced dermal blood flow in healthy subjects. Clin Pharmacol Drug Dev 10(5):440\u2013452","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1602_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bcp.12704","volume":"80","author":"L Buntinx","year":"2015","unstructured":"Buntinx L, Vermeersch S, de Hoon J (2015) Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model. Br J Clin Pharmacol 80(5):992\u20131000","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1602_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/0333102413517773","volume":"34","author":"K Ibrahimi","year":"2014","unstructured":"Ibrahimi K, Vermeersch S, Danser A, Villal\u00f3n CM, van den Meiracker AH, de Hoon J et al (2014) Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead. Cephalalgia 34(7):514\u2013522","journal-title":"Cephalalgia"},{"issue":"2","key":"1602_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.0000000000001142","volume":"84","author":"K Ibrahimi","year":"2015","unstructured":"Ibrahimi K, van Oosterhout WP, van Dorp W, Danser AH, Garrelds IM, Kushner SA et al (2015) Reduced trigeminovascular cyclicity in patients with menstrually related migraine. Neurology 84(2):125\u2013131","journal-title":"Neurology"},{"issue":"8","key":"1602_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/jnnp-2021-327992","volume":"93","author":"LS de Vries","year":"2022","unstructured":"de Vries LS, Al-Hassany L, Ferrari MD, Terwindt GM, MaassenVanDenBrink A (2022) CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab. J Neurol Neurosurg Psychiatry 93(8):911\u2013912","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1602_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/head.14313","volume":"62","author":"M Ashina","year":"2022","unstructured":"Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M et al (2022) Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: a subgroup analysis. Headache 62(5):624\u2013633","journal-title":"Headache"},{"issue":"2","key":"1602_CR15","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644","journal-title":"Physiol Rev"},{"issue":"12","key":"1602_CR16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102416668659","volume":"37","author":"K Ibrahimi","year":"2017","unstructured":"Ibrahimi K, Vermeersch S, Frederiks P, Geldhof V, Draulans C, Buntinx L et al (2017) The influence of migraine and female hormones on capsaicin-induced dermal blood flow. Cephalalgia 37(12):1164\u20131172","journal-title":"Cephalalgia"},{"key":"1602_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.maturitas.2020.12.012","volume":"145","author":"LS de Vries","year":"2021","unstructured":"de Vries LS, Rubio-Beltr\u00e1n E, MaassenVanDenBrink A (2021) Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman\u2019s life: Implications for the efficacy and safety of novel antimigraine medications. Maturitas 145:73\u201377","journal-title":"Maturitas"},{"issue":"3","key":"1602_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284\u2013294","journal-title":"Lancet Neurol"},{"issue":"2","key":"1602_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jcph.1511","volume":"60","author":"W Kielbasa","year":"2020","unstructured":"Kielbasa W, Quinlan T (2020) Population pharmacokinetics of galcanezumab, an Anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol 60(2):229\u2013239","journal-title":"J Clin Pharmacol"},{"key":"1602_CR20","doi-asserted-by":"publisher","first-page":"686398","DOI":"10.3389\/fneur.2021.686398","volume":"12","author":"E Rivera-Mancilla","year":"2021","unstructured":"Rivera-Mancilla E, Al-Hassany L, Villal\u00f3n CM, MaassenVanDenBrink A (2021) Metabolic aspects of migraine: association with obesity and diabetes mellitus. Front Neurol 12:686398","journal-title":"Front Neurol"},{"key":"1602_CR21","unstructured":"Eli Lilly and Company (2019) Galcanezumab (Emgality\u00ae): US prescribing information. Available from: \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761063s003lbl.pdf\n[cited 29 Apr 2023]"},{"key":"1602_CR22","unstructured":"Teva Pharmaceuticals GmbH (2019) Summary of Product Characteristics: Fremanezumab (AJOVY). Available from: \nhttps:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ajovy-epar-product-information_en.pdf\n[cited 29 Apr 2023]"},{"issue":"13","key":"1602_CR23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511\u20131522","journal-title":"Cephalalgia"},{"issue":"1","key":"1602_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","volume":"20","author":"V Favoni","year":"2019","unstructured":"Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, De Boer I et al (2019) CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 20(1):27","journal-title":"J Headache Pain"},{"key":"1602_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s42399-020-00300-5","volume":"2","author":"N Joshi","year":"2020","unstructured":"Joshi N, McAree M, Klimowich K, Cahill K, Janora D (2020) Oral Candidiasis in a Migraine Patient Taking Erenumab and Galcanezumab: a Case Report. SN Compr Clin Med 2:658\u2013661","journal-title":"SN Compr Clin Med"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01602-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T07:02:07Z","timestamp":1686294127000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01602-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01602-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"8 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No additional approval from the Ethics Board was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of the current case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Linda Al-Hassany and Nazia Karsan declare no conflict of interest with respect to the research, authorship, and\/or publication of this article.Christian Lampl reports consultation fees from Allergan\/Abbvie, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva.Peter J Goadsby reports, over the last 36\u00a0months, a grant from Celgene, and personal fees from Aeon Biopharma, Allergan\/Abbvie, Amgen, Biodelivery Sciences International, Biohaven Pharmaceuticals Inc., CoolTech LLC, Dr Reddys, Eli-Lilly, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, Novartis, Praxis, Sanofi, Satsuma and Teva Pharmaceuticals, and personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric, and fees for educational materials from CME Outfitters, Omnia Education, WebMD, and publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer, and for medicolegal advice in headache, and a patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.Antoinette MaassenVanDenBrink received research grants and\/or consultation fees from Allergan, Amgen\/Novartis, Eli Lilly, Satsuma, Teva, Tonix, and ATI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}